- France
- /
- Medical Equipment
- /
- ENXTPA:ALMKT
Mauna Kea Technologies SA's (EPA:ALMKT) Share Price Could Signal Some Risk
With a median price-to-sales (or "P/S") ratio of close to 1.9x in the Medical Equipment industry in France, you could be forgiven for feeling indifferent about Mauna Kea Technologies SA's (EPA:ALMKT) P/S ratio of 2x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
Check out our latest analysis for Mauna Kea Technologies
How Has Mauna Kea Technologies Performed Recently?
With revenue growth that's superior to most other companies of late, Mauna Kea Technologies has been doing relatively well. It might be that many expect the strong revenue performance to wane, which has kept the P/S ratio from rising. If not, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Mauna Kea Technologies.Do Revenue Forecasts Match The P/S Ratio?
In order to justify its P/S ratio, Mauna Kea Technologies would need to produce growth that's similar to the industry.
If we review the last year of revenue growth, the company posted a terrific increase of 38%. The latest three year period has also seen an excellent 61% overall rise in revenue, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing revenue over that time.
Shifting to the future, estimates from the one analyst covering the company suggest revenue growth is heading into negative territory, declining 22% over the next year. With the industry predicted to deliver 5.6% growth, that's a disappointing outcome.
In light of this, it's somewhat alarming that Mauna Kea Technologies' P/S sits in line with the majority of other companies. Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock right now. There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the negative growth outlook.
What Does Mauna Kea Technologies' P/S Mean For Investors?
It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.
While Mauna Kea Technologies' P/S isn't anything out of the ordinary for companies in the industry, we didn't expect it given forecasts of revenue decline. With this in mind, we don't feel the current P/S is justified as declining revenues are unlikely to support a more positive sentiment for long. If we consider the revenue outlook, the P/S seems to indicate that potential investors may be paying a premium for the stock.
Before you settle on your opinion, we've discovered 5 warning signs for Mauna Kea Technologies (1 is potentially serious!) that you should be aware of.
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALMKT
Mauna Kea Technologies
A medical device company, manufactures and sells medical devices in Europe and internationally.
Medium-low and slightly overvalued.